Prostate Specific Antigen-α1-Antichymotrypsin Complex (PSA-ACT); ≥95% pure

This preparation of Prostate Specific Antigen - a1 Antichymotrypsin Complex (PSA-ACT Complex) is purified from human seminal fluid (PSA) and human plasma (ACT). The material is provided as a liquid in 10 Sodium Acetate, 150 mM Sodium Chloride, 0.1% Sodium Azide, pH 5.6. Purity is ≥95% by SDS-PAGE.

As a primary manufacturer, Scripps is able to offer research- and manufacturing-scale quantities of high quality antigens and antibodies. Materials are produced, packaged, and shipped from our facility in San Diego, California.

Click here to inquire about Bulk Pricing Discounts

Prostate Specific Antigen (PSA), a glycoprotein of the glandular kallikrein family, is a serine protease with chymotrypsin-like enzymatic activity. It has a molecular weight of approximately 33,000-34,000 Da and is found primarily in prostate tissue and seminal fluid. Serum levels of PSA are very low in healthy individuals (0-4 ng/ml), but are often elevated in malignant and benign prostatic disease. As such, immunoassays for serum levels of PSA have proven useful in the diagnosis and follow-up of prostate cancer.

PSA released into circulation is present as unbound, free PSA (fPSA) or bound to serum protease inhibitors, such as α1-Antichymotrypsin (ACT) and α2-Macroglobulin (A2M). Research indicates that immunoassays for serum levels of PSA alone cannot be relied on to distinguish prostate cancer from benign prostatic hyperplasia (BPH). Serum levels of PSA-ACT complex are reportedly higher in patients with prostate cancer than in those with BPH. As such, measuring the ratio of PSA-ACT to fPSA in patient samples is proving valuable in the differential diagnosis of prostate cancer. In addition, immunoassays for PSA-A2M serum levels may prove valuable in prostate cancer diagnosis, but further study is required.

***Read how the addition of information from biological factors significantly increases the clinical utility of the serum PSA test: Scripps News Vol. 16 No. 2